Drug Co. Investors Seek OK For Early $3.8M Settlement
Law360, New York (April 17, 2017, 2:55 PM EDT) -- A putative class of investors in Amicus Therapeutics Inc. who said the company’s misleading statements about their interaction with the U.S. Food and Drug Administration amounted to securities fraud asked a New Jersey federal court on Friday to approve a $3.75 million settlement that would end the litigation before the court even considered dismissal.
The shareholders said their deal with Amicus would get them more than 8 percent of the $44 million in damages they say they incurred in the last two weeks of September 2015, when Amicus and officers John Crowley and Jay Barth misled shareholders about the regulatory approval...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!